Abstract
γ-Secretase proteolyzes a variety of membrane-associated fragments derived from type I integral membrane proteins, including the amyloid β-protein precursor, involved in Alzheimers disease, and the Notch receptor, critical for cellular differentiation. This protease is composed of four integral membrane proteins: presenilin, nicastrin, Aph-1 and Pen-2. Assembly of these four components leads to presenilin autoproteolysis into two subunits, each of which contributes one aspartate to the active site of an aspartyl protease. The protease contains an initial docking site for substrate, where it binds prior to passing between the two presenilin subunits to the internal water-containing active site. The extracellular region of nicastrin also interacts with the N-terminus of the substrate as an essential step in substrate recognition and processing. Modulation of APP processing without interfering with Notch signaling is an important therapeutic goal, and allosteric sites on the protease allow such selective modulation. A better structural and mechanistic understanding of γ-secretase should ultimately allow structure-based design of more potent and selective modulators.
Current Topics in Medicinal Chemistry
Title: γ-Secretase: Structure, Function, and Modulation for Alzheimers Disease
Volume: 8 Issue: 1
Author(s): Michael S. Wolfe
Affiliation:
Abstract: γ-Secretase proteolyzes a variety of membrane-associated fragments derived from type I integral membrane proteins, including the amyloid β-protein precursor, involved in Alzheimers disease, and the Notch receptor, critical for cellular differentiation. This protease is composed of four integral membrane proteins: presenilin, nicastrin, Aph-1 and Pen-2. Assembly of these four components leads to presenilin autoproteolysis into two subunits, each of which contributes one aspartate to the active site of an aspartyl protease. The protease contains an initial docking site for substrate, where it binds prior to passing between the two presenilin subunits to the internal water-containing active site. The extracellular region of nicastrin also interacts with the N-terminus of the substrate as an essential step in substrate recognition and processing. Modulation of APP processing without interfering with Notch signaling is an important therapeutic goal, and allosteric sites on the protease allow such selective modulation. A better structural and mechanistic understanding of γ-secretase should ultimately allow structure-based design of more potent and selective modulators.
Export Options
About this article
Cite this article as:
Wolfe S. Michael, γ-Secretase: Structure, Function, and Modulation for Alzheimers Disease, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334024
DOI https://dx.doi.org/10.2174/156802608783334024 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptidyl Arginine Deiminases and Neurodegenerative Diseases
Current Medicinal Chemistry Autism - A Comprehensive Array of Prominent Signs and Symptoms
Current Pharmaceutical Design Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets New Approaches for the Treatment of Mental Disorders Comorbid with Inflammatory Diseases
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Current Approaches for Antipsychotics in Drug Discovery: Hope Beyond the Dopamine D2 Receptor?)
Current Pharmaceutical Design Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers
Clinical Cancer Drugs In Vivo Human Amyloid Imaging
Current Alzheimer Research Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Current Alzheimer Research Affordable Antiretroviral Drugs for the Under-Served Markets: How to Expand Equitable Access Against the Backdrop of Challenging Scenarios?
Current HIV Research DJ-1: A New Comer in Parkinsons Disease Pathology
Current Molecular Medicine Nanoneuromedicines for Neurodegenerative Diseases
Nanoscience & Nanotechnology-Asia The AICD Interacting Protein DAB1 is Up-Regulated in Alzheimer Frontal Cortex Brain Samples and Causes Deregulation of Proteins Involved in Gene Expression Changes
Current Alzheimer Research Advances in Studies on Neurodegenerative Diseases and their Treatments
Current Topics in Medicinal Chemistry Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures
Current Drug Delivery Ameliorative Effects of GW1929, a Nonthiazolidinedione PPARγ Agonist,on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury
Current Neurovascular Research MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Enzyme Inhibitors as the Attractive Targets for the Treatment of Various Diseases
Current Medicinal Chemistry Machine Learning-Based Virtual Screening Strategy RevealsSome Natural Compounds as Potential PAK4 Inhibitors in Triple Negative Breast Cancer
Current Proteomics